Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inactivated Hepatitis A Vaccine, Lu8 Strain
- Development stage
- Phase 4
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
An inactivated hepatitis A vaccine using the Lu8 strain of the hepatitis A virus. Hepatitis A vaccines provide active immunization against disease caused by the hepatitis A virus (HAV).
- Brand names
- Weisairuian
- Other names
- Inactivated HAV Antigen (Strain LV8)
02
Targets
TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on Inactivated Hepatitis A Vaccine, Lu8 Strain.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inactivated Hepatitis A Vaccine, Lu8 Strain.